# Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

> **NCT02588859** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1200 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02588859
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-30
- **Primary completion:** 2016-12-26
- **Final completion:** 2016-12-26
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2017-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588859, "Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02588859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*